Obe-cel in Refractory Progressive Forms of Multiple Sclerosis (NCT07139743)
A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies. Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion. Participants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.
Who can join: Review the eligibility criteria below.
Location: Stanford University — Redwood City, California
Age range: 18 Years to 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Stanford University — Redwood City, California
- Hospital Universitario Vall d'Hebron - PPDS — Barcelona,
- Hospital Universitari i Politecnic La Fe de Valencia — Valencia,
- Addenbrooke's Hospital — Cambridge,
- Western General Hospital Edinburgh - PPDSE Edinburgh — Edinburgh,
- The National Hospital for Neurology & Neurosurgery — London,
- Royal Hallamshire Hospital — Sheffield,
📞 Contact the Study Coordinator
Phone: +44 (0)203 911 4385
Email: clinicaltrials@autolus.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Progressive Multiple Sclerosis
- A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis — San Francisco, California
- ABA-101 in Participants With Progressive Multiple Sclerosis — Baltimore, Maryland
- Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) — Darlinghurst, New South Wales
- Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients — Ann Arbor, Michigan
Explore by condition: All Progressive Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.